RTP 200
Alternative Names: RTP-200Latest Information Update: 21 Feb 2025
At a glance
- Originator ResoTher Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 28 Jan 2025 Early research in Unspecified in Denmark (unspecified route) (ResoTher Pharma pipeline, January 2025)